Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Sosne

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Investigative Ophthalmology & Visual Science|June 28, 2005
Thymosin-beta4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injuryGabriel Sosne, Patricia L Christopherson, Ronald P Barrett, et al.
Annals of the New York Academy of Sciences|October 12, 2012
Thymosin β4: a potential novel dry eye therapyGabriel Sosne, Ping Qiu, George W Ousler, et al.
Cells|December 24, 2021
Adjunctive Thymosin Beta-4 Treatment Influences PMN Effector Cell Function during <i>Pseudomonas aeruginosa</i>-Induced Corneal InfectionYuxin Wang, Thomas W Carion, Abdul Shukkur Ebrahim, et al.
International Journal of Molecular Sciences|October 23, 2021
Adjunctive Thymosin Beta-4 Treatment Influences MΦ Effector Cell Function to Improve Disease Outcome in <i>Pseudomonas aeruginosa</i>-Induced KeratitisYuxin Wang, Thomas W Carion, Abdul Shukkur Ebrahim, et al.
Experimental Eye Research|April 25, 2006
Thymosin beta4 inhibits benzalkonium chloride-mediated apoptosis in corneal and conjunctival epithelial cells in vitroGabriel Sosne, Abdul-Rahman Albeiruti, Brian Hollis, et al.
International Journal of Molecular Sciences|January 8, 2023
0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical TrialGabriel Sosne, Hynda K Kleinman, Clark Springs, et al.
Frontiers in Immunology|October 9, 2024
Activation of pro-resolving pathways mediate the therapeutic effects of thymosin beta-4 during <i>Pseudomonas aeruginosa</i>-induced keratitisYuxin Wang, Loveleen Banga, Abdul Shukkur Ebrahim, et al.
Experimental Eye Research|April 13, 2002
Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injuryGabriel Sosne, Elizabeth A Szliter, Ronald Barrett, et al.
Scientific Reports|July 14, 2018
RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye modelChae Eun Kim, Hynda K Kleinman, Gabriel Sosne, et al.
International Journal of Molecular Sciences|September 23, 2020
Antimicrobial Effects of Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy in <i>Pseudomonas aeruginosa</i> Induced KeratitisThomas W Carion, Abdul Shukkur Ebrahim, Spandana Alluri, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Investigative Ophthalmology & Visual Science|June 28, 2005
Thymosin-beta4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injuryGabriel Sosne, Patricia L Christopherson, Ronald P Barrett, et al.
Annals of the New York Academy of Sciences|October 12, 2012
Thymosin β4: a potential novel dry eye therapyGabriel Sosne, Ping Qiu, George W Ousler, et al.
Cells|December 24, 2021
Adjunctive Thymosin Beta-4 Treatment Influences PMN Effector Cell Function during <i>Pseudomonas aeruginosa</i>-Induced Corneal InfectionYuxin Wang, Thomas W Carion, Abdul Shukkur Ebrahim, et al.
International Journal of Molecular Sciences|October 23, 2021
Adjunctive Thymosin Beta-4 Treatment Influences MΦ Effector Cell Function to Improve Disease Outcome in <i>Pseudomonas aeruginosa</i>-Induced KeratitisYuxin Wang, Thomas W Carion, Abdul Shukkur Ebrahim, et al.
Experimental Eye Research|April 25, 2006
Thymosin beta4 inhibits benzalkonium chloride-mediated apoptosis in corneal and conjunctival epithelial cells in vitroGabriel Sosne, Abdul-Rahman Albeiruti, Brian Hollis, et al.
International Journal of Molecular Sciences|January 8, 2023
0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical TrialGabriel Sosne, Hynda K Kleinman, Clark Springs, et al.
Frontiers in Immunology|October 9, 2024
Activation of pro-resolving pathways mediate the therapeutic effects of thymosin beta-4 during <i>Pseudomonas aeruginosa</i>-induced keratitisYuxin Wang, Loveleen Banga, Abdul Shukkur Ebrahim, et al.
Experimental Eye Research|April 13, 2002
Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injuryGabriel Sosne, Elizabeth A Szliter, Ronald Barrett, et al.
Scientific Reports|July 14, 2018
RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye modelChae Eun Kim, Hynda K Kleinman, Gabriel Sosne, et al.
International Journal of Molecular Sciences|September 23, 2020
Antimicrobial Effects of Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy in <i>Pseudomonas aeruginosa</i> Induced KeratitisThomas W Carion, Abdul Shukkur Ebrahim, Spandana Alluri, et al.
Pageof 4